This new collaboration builds on Wave’s ongoing research and development in splice correction programmes, including its lead DMD programme, …
Wave enter into collaboration with Deep Genomics to expand research programmeRead More

11 April 2018 by abzali123
This new collaboration builds on Wave’s ongoing research and development in splice correction programmes, including its lead DMD programme, …
Wave enter into collaboration with Deep Genomics to expand research programmeRead More

6 April 2018 by abzali123
Action Duchenne supported the preclinical funding and Phase 1 clinical trials of this innovative steroid-like intervention on Duchenne muscular …
VISION-DMD newsletter launched at Phase 2 of clinical trial of VamoroloneRead More

4 April 2018 by abzali123
Action Duchenne have been asked by Adelphi Values, to help recruit people from the Duchenne community, for their important study. The UK has a …
Adelphi Values would like to interview people from the Duchenne communityRead More

4 April 2018 by abzali123
The Ulster University have approached Action Duchenne and our wonderful community to take part in an important research study which could benefit the …
Give your valuable experiences of caring and supporting a young person with DuchenneRead More

4 April 2018 by abzali123
‘A checklist to a good transition’ joins the suite of resources compiled by 'Together for Short Lives', aimed at improving the experiences …
‘Together for short lives’ launches new transition checklistRead More

23 March 2018 by abzali123
Your views matter about bone health. There’s still time to take part in an important survey to improve bone health in Duchenne. The links below will …

22 March 2018 by abzali123
ReveraGen has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for vamorolone (VBP15) for the treatment …
ReveraGen receives FDA fast track designation for VamoroloneRead More

22 March 2018 by abzali123
We recently emailed you to update you on the Managed Access Agreement for Translarna. We know that some of you had questions about this. To try and …
Translarna Managed Access Agreement frequently asked questionsRead More

16 March 2018 by abzali123
Did you realise that disabled people are TWICE as likely to be unemployed than non-disabled people? Are you aware that there are currently 1.8 …
Papworth Trust’s Disability in the UK: Facts and Figures 2018Read More

13 March 2018 by abzali123
Last month the Ethics and Social Science Genomics England Clinical Interpretation Partnership (GeCIP) held its first national community meeting in …
Ethics and Social Science – a community in partnershipRead More

13 March 2018 by abzali123
Wave Life Sciences have reported financial results for the fourth quarter and full year ended December 31, 2017, and provided a business …
Wave Life Sciences financial results and business updateRead More

9 March 2018 by abzali123
What is the EAMS? The Early Access to Medicines Scheme (EAMS) aims to give patients with life threatening or seriously debilitating conditions, access …
You have an important voice – make it heard in the discussion about Raxone and the EAMSRead More
Action Duchenne
2nd Floor
South
One Castle Park
Tower Hill
Bristol
BS2 OJA
0300 102 1762
info@actionduchenne.org
